Aurobindo Pharma Limited Latest Updates

Q1 FY27 Financial Results & Profit Surge On August 5, 2026, Aurobindo Pharma reported a 25.2% year-on-year increase in consolidated net profit (PAT) to ₹1,032 crore for the first quarter ended June 30, 2026. Consolidated revenue from operations grew 16.3% YoY to ₹9,150 crore, while operating EBITDA rose 20% YoY to ₹1,924 crore with EBITDA margins expanding 60 basis points to 21.0%. Top-line growth was anchored by the European formulations vertical (+25.6% YoY to ₹2,937 crore) and Growth Markets (+37.7% YoY). US FDA Inspection Cleared for Aurolife Pharma On August 17, 2026, the company notified stock exchanges that its step-down subsidiary, Aurolife Pharma LLC, received an Establishment Inspection Report (EIR) from the US FDA for its manufacturing facility located in Raleigh, North Carolina. The inspection was successfully closed with a Voluntary Action Indicated (VAI) classification, clearing the regulatory path for pending product applications in inhalers, dermatology, and transdermal patches. Regulatory Action on Eugia Pharma Unit-I On August 14, 2026, Aurobindo Pharma disclosed that the US FDA issued a Warning Letter to the formulation manufacturing facility (Unit-I) of its subsidiary, Eugia Pharma Specialities Limited, located in Telangana. The unit contributes approximately 2% to the group’s overall consolidated revenue. The company confirmed that the regulatory status does not disrupt existing commercial supplies to the US market and that it is actively coordinating remediation measures with the FDA. Internal Corporate Amalgamation Scheme The Board of Directors approved a Scheme of Amalgamation to merge two step-down wholly-owned subsidiaries, Eugia Steriles Private Limited and Eugia SEZ Private Limited, into Eugia Pharma Specialities Limited.